AB Science
AB · Euronext Paris · France
Public Market Listing
Live quotes, historical charts, and market capitalization for AB Science are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | $0.6M | $10M | $10M | $5.3M | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.3M | $2.3M | $11M | $1.7M | report ↗ |
AB Science reported FY2025 revenue of $1.27M (€1.174M), up 10% YoY, and R&D spend of $2.26M (€2.090M), with cash and equivalents of $11.01M (€10.2M) at year-end. The company recorded an operating loss of €3.8M excluding non-recurring items, down 38% YoY, and a net loss of €1.557M, down 80% YoY; structured data show a quarterly net burn of $1.69M, with an additional €3.2M raised in April 2026.
During the period, key clinical events included authorizations to start the confirmatory Phase 3 masitinib trial in ALS and a Phase 3 trial in metastatic prostate cancer, plus published subgroup data on masitinib in ALS showing survival and functional benefits. In acute myeloid leukaemia, AB8939 progressed through Phase 1/2 stages, with four consecutive responses reported in combination with venetoclax, and received EU orphan drug designation. The company also reached a final agreement with financial creditors to defer loan repayments, completed several capital raises, and announced a voluntary temporary suspension of European trial recruitment while prioritising Phase 3 masitinib in ALS and Phase 1 AB8939 in AML.